Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.

被引：0
|
作者：
Konecny, Gottfried E.
Hendrickson, Andrea Elisabeth Wahner
Winterhoff, Boris
Chander, Cinthiya
Bilic, Sanela
Davenport, Simon
Chung, Adrine
Miller, Lei-Lani
Press, Michael F.
Letrent, Stephen P.
Slamon, Dennis J.
机构：
[1] Univ Calif Los Angeles Med Ctr, Santa Monica, CA USA
[2] Mayo Clin, Rochester, MN USA
[3] Univ Minnesota, Div Gynecol Oncol, Minneapolis, MN USA
[4] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA USA
[5] Vanadro LLC, Urbandale, IA USA
[6] Univ Southern Calif, Los Angeles, CA USA
[7] Translat Res Oncol US, Los Angeles, CA USA
[8] TORL Biotherapeut, Culver City, CA USA
[9] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3082
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PRELIMINARY PHASE 1 PHARMACOKINETIC (PK) AND EXPOSURE-RESPONSE (ER) ANALYSES RESULTS OF ABBV-085, AN ANTIBODY DRUG CONJUGATE (ADC), IN PATIENTS WITH ADVANCED SOLID TUMORS.
    Polepally, A.
    Gopalakrishnan, S.
    Robinson, R.
    Myzak, M.
    Demetri, G.
    Villalobos, V.
    Menon, R.
    Kasichayanula, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S99 - S99
  • [32] Preliminary results of PROCLAIM-CX-2009, a first-in-human, dose-finding study of the Probody drug conjugate CX-2009 in patients with advanced solid tumors
    Meric-Bernstam, Funda
    Boni, Valentina
    Spira, Alexander I.
    Sanborn, Rachel E.
    Arkenau, H-Tobias
    Sweis, Randy
    Burris, Howard
    Li, Rachel
    Yalamanchili, Sreeni
    Will, Matthias
    Liu, Joyce F.
    Harding, James J.
    Gautam, Pratigya
    CANCER RESEARCH, 2019, 79 (13)
  • [33] Results of a completed first-in-human phase Ib dose-escalation study of oral CBL0137 in patients with advanced solid tumors.
    Fedyanin, Mikhail
    Tryakin, Alexey
    Lisyanskaya, Alla Sergeevna
    Solovyeva, Ekaterina
    Fadeeva, Natalia
    Gladkov, Oleg
    Moiseyenko, Vladimir
    Cheporov, Sergey, V
    Shpigotskaya, Polina
    Purmal, Andrei
    Miller, Langdon L.
    Leonov, Andrey
    Zakurdaeva, Kristina
    Gurova, Katerina
    Gudkov, Andrei
    Tjulandin, Sergei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors.
    Powderly, John D.
    Jang, Sekwon
    Lohr, Joanna
    Spira, Alexander, I
    Bohac, Gerry C.
    Sharma, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met-targeting antibody-drug conjugate, in advanced solid tumors
    Sharma, Manish
    Kuboki, Yasutoshi
    Camidge, D. Ross
    Perets, Ruth
    Sommerhalder, David
    Yamamoto, Noboru
    Bar, Jair
    Parikh, Apurvasena
    Li, Rui
    Thiele, Gladys Morrison
    Aristide, Martha Raluca Neagu
    Freise, Kevin Jay
    Powderly, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors
    Wang, Yakun
    Gong, Jifang
    Lin, Rongbo
    Zhao, Shen
    Wang, Jufeng
    Wang, Qianli
    Zhang, Yanqiao
    Su, Dan
    Zhang, Jingdong
    Dong, Qian
    Lin, Ling
    Tian, Wen
    Chen, Ying
    Yang, Yang
    Zhang, Xueyuan
    Wan, Xuechao
    Gao, Jinfeng
    An, Na
    Jansen, Valerie Malyvanh
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
    Naing, Aung
    Gainor, Justin F.
    Gelderblom, Hans
    Forde, Patrick M.
    Butler, Marcus O.
    Lin, Chia-Chi
    Sharma, Sunil
    de Olza, Maria Ochoa
    Varga, Andrea
    Taylor, Matthew
    Schellens, Jan H. M.
    Wu, Hongqian
    Sun, Haiying
    Silva, Antonio P.
    Faris, Jason
    Mataraza, Jennifer
    Cameron, Scott
    Bauer, Todd M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [38] EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors
    Aggarwal, Charu
    Azzoli, Christopher G.
    Spira, Alexander I.
    Solomon, Benjamin J.
    Le, Xiuning
    Rolfo, Christian
    Planchard, David
    Felip, Enriqueta
    Wu, Yi-Long
    Ahn, Myung-Ju
    Seiwert, Tanguy Y.
    Goto, Koichi
    Azaro, Analia
    Lissa, Delphine
    Hamid, Oday
    McGrath, Lara
    Maudsley, Rhiannon
    Arnaldez, Fernanda I.
    Grenga, Italia
    Massarelli, Erminia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors.
    Falchook, Gerald Steven
    Liang, Yan
    Harvey, R. Donald
    Fu, Siqing
    Weitao, Yao
    Qin, Yan-Ru
    Zhang, Xiaojing
    Henry, Jason Timothy
    Zou, Qingping
    Shan, Boyao
    Liang, Pan
    Wang, Chen
    Li, Wenjia
    Pamuklar, Zehra Nurgul
    Pei, Yi
    Chang, Zhiwei
    Wang, Jiaqiang
    Piha-Paul, Sarina A.
    Bhave, Manali A.
    Yin, Yongmei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] First-in-human phase 1 study of a phosphatidylserine-targeting small molecule drug conjugate (T-1201) in patients with advanced solid tumors
    Wang, Hui-Ching
    Yeh, Yu-Min
    Du, Jeng-Shiun
    Yeh, Tsung-Jang
    Tsai, Jui-Hung
    Gau, Yu-Chin
    Wu, Shang Yin
    Chen, Li-Tzong
    Li, Hsiao-Fang
    Su, Wu-Chou
    CANCER RESEARCH, 2024, 84 (07)
12345